Robin Wyn

Mr. Robin Wyn


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Animals
Verified
Journal Article
Open access
PDF file
AWAndrea Wright
Andrea Wright
AHAndrew Hillier
Andrew Hillier
JLJonathan Lambert
Jonathan Lambert
KMKennedy Mwacalimba
Kennedy Mwacalimba
NLNatalie Raquel Lloyd
Natalie Raquel Lloyd
RWRobin Wyn
Robin Wyn
Oclacitinib is an oral therapy indicated for pruritus associated with allergic or atopic dermatitis in dogs. This study sought to assess pet owners’ perceptions of the relative convenience and value of the conventional film-coated formulation and the chewable formulation. A quantitative discrete-choice experimental methodology was applied, comparing (conventional, film-coated) oclacitinib versus chewable oclacitinib using unbranded treatment profiles. Initially, a qualitative interview phase with pet owners and veterinarians was conducted to develop detailed treatment profiles. Subsequently, pet owners participated in a quantitative survey. Overall, 1590 pet owners provided survey responses. Most respondents (62%) reported having experienced challenges administering tablet-based therapies to their dog(s). Half of all respondents (52%) had experience administering flavoured or chewable tablets to their dog. Comparing oclacitinib and chewable oclacitinib (with or without associated costs), the majority of the respondents preferred the chewable formulation in all regions across short-term and long-term scenarios (≥58%; all p < 0.05). The current research is one of few survey-driven studies for treatment preferences in companion animal medicine. Veterinarians may offer chewable or palatable treatment options where available, with potential positive impacts on convenience, compliance, outcomes, quality of life, and the human–animal bond.

31 July 2024 in Animals
Verified
Journal Article
Open access
PDF file
EGEdwina Gildea
Edwina Gildea
RWRobin Wyn
Robin Wyn
KWKatherine Walker
Katherine Walker
FAFrancis Adriaens
Francis Adriaens
DLDuncan X Lascelles
Duncan X Lascelles
Bedinvetmab (Librela®) represents a new class of canine osteoarthritis pain therapy. The aim of this study was to understand patient selection, usage behaviours, and satisfaction amongst veterinarians using bedinvetmab. Overall, 1932 patient record forms (PRF) were collected from 375 veterinarians across five countries in Europe. Veterinarians were asked to provide 5–7 PRF representing an average patient prescribed bedinvetmab. Veterinarian satisfaction with bedinvetmab usage averaged 8.0 out of 10.0 across all countries. Dissatisfaction as a reason for discontinuation was less than 1% for veterinarians. Veterinarians prescribed bedinvetmab broadly, across patient severity stages, weights, and ages. Adherence to monthly dosing per the product label was over 99%, and compliance with bedinvetmab treatment regimens was 85%. Following initiation of bedinvetmab, the proportion of patients requiring multiple pharmacological therapies for osteoarthritis pain fell from 47% to 31% (p < 0.05). After initiation of bedinvetmab, the mean total number of pharmacological therapies per patient across the population was 1.3, a reduction from 1.9 pre-treatment (p < 0.05). This investigation provides evidence on the benefit of bedinvetmab use post-launch in a broad population of dogs across the five most populous countries in western Europe. Compliance and satisfaction appear high and the use of other analgesic therapies to treat osteoarthritis pain is reduced in most cases following administration of bedinvetmab.

21 June 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JNJoanne B. Tutein Nolthenius
Joanne B. Tutein Nolthenius
AGAnnabel Griffiths
Annabel Griffiths
ODOlivia Dodd
Olivia Dodd
RWRobin Wyn
Robin Wyn
AEAshley Enstone
Ashley Enstone
JWJohn Whalen
John Whalen
Introduction Activated phosphoinositide 3-kinase δ (PI3Kδ) syndrome (APDS) is an ultra-rare inborn error of immunity. APDS is a chronic, heterogeneous, and progressive disease, with individuals experiencing different combinations of multisystemic clinical manifestations which advance over time. To date, there are no published utility values for APDS and there are limited data detailing the long-term effects and impact of APDS on health-related quality of life (HRQoL). This study sought to quantify the impact of individual and combined manifestations on the HRQoL of people with APDS. Methods To mitigate the challenges of measuring HRQoL in a rare disease, health state vignettes were developed through interviews with people with APDS and the published literature, and validated by experts, to represent individual or combinations of manifestations frequently experienced by people with APDS. Two valuation methods were then employed to elicit utility values for the health states: EQ-5D with clinical experts from France, Spain, and the UK (N = 4), and time trade-off (TTO) with members of the UK general public (N = 100). Results The results of both EQ-5D and TTO exercises highlight the substantial HRQoL impact of APDS, particularly in those experiencing multiple concurrent manifestations or those diagnosed with lymphoma. Mean utility values ranged from 0.897 to − 0.109 in the EQ-5D exercise and 0.870 to 0.330 in the TTO exercise. Overall, the ranking of the health states by utility values was generally consistent between EQ-5D and TTO exercises. However, points of variance were observed for utility values for severe health states, e.g. those including lymphoma (one of the primary causes of death in APDS) ranged from 0.430 to − 0.109 in the TTO and EQ-5D exercises, respectively. Conclusion This is the first study to indirectly elicit utility values in APDS through valuation by the general population and clinical experts. This expands on the current literature for APDS by providing an overview of how HRQoL declines with disease progression and increasing number of manifestations.

6 July 2025 in Animals
Verified
Journal Article
Open access
PDF file
CTConstantina N. Tsokana
Constantina N. Tsokana
George ValiakosGeorge Valiakos
George Valiakos
KMKennedy Mwacalimba
Kennedy Mwacalimba
DRDanielle Riley
Danielle Riley
AEAshley Enstone
Ashley Enstone
AWAndrea Wright
Andrea Wright
Cat owners are involved in their cats’ healthcare, including the prevention of parasitic diseases. However, a comprehensive understanding of their preferences for feline antiparasitics is lacking. This study addresses this gap through a multifaceted methodology comprising three phases. In Phase 1, the physical properties and usability aspects of seven topical antiparasitic formulations were assessed. Within Phase 2, an ease-of-use study was conducted to evaluate the cat owners’ application experience with deidentified products representing three topical antiparasitics. Phase 3 included the identification and validation of product attributes most valued by pet owners through interviews with cat owners and veterinary experts. The product attributes identified informed the subsequent quantitative discrete choice experiment (DCE), which involved 1040 cat owners from different countries (Australia/New Zealand, Canada, Greece/Spain, and the UK) and aimed to analyze their preferences based on choices among product profiles mirroring four topical antiparasitics: selamectin–sarolaner, moxidectin–fluralaner, moxidectin–imidacloprid, and eprinomectin–esafoxolaner–praziquantel. Phase 1 showed that the selamectin–sarolaner formulation exhibits minimal odor, less stickiness, and less drying time. The ease-of-use study (Phase 2) showed that the blinded product representing the selamectin–sarolaner formulation was characterized by seamless application, rapid dispensing, and a sense of control during application. The quantitative DCE study (Phase 3) indicated a preference for the product profile mirroring the selamectin–sarolaner formulation among a global sample of cat owners. Demographic characteristics such as gender, age, and insurance status influenced their preferences. Key predictors for preferring the selamectin–sarolaner formulation over at least one comparator treatment included the ability to confirm successful administration, age restrictions, ease of application, and the time before the cat could sit on furniture following administration. These findings suggest that cat owners prioritize ease of use, safety, and overall user experience, providing valuable guidance for veterinary practitioners to make informed treatment recommendations.

22 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CTConstantina N. Tsokana
Constantina N. Tsokana
George ValiakosGeorge Valiakos
George Valiakos
KMKennedy Mwacalimba
Kennedy Mwacalimba
DRDanielle Riley
Danielle Riley
AEAshley Enstone
Ashley Enstone
AWAndrea Wright
Andrea Wright
Cat owners are involved in their cats’ healthcare, including the prevention of parasitic diseases. However, a comprehensive understanding of their preferences for feline antiparasitics is lacking. This study addresses this gap through a multifaceted methodology comprising three phases. In Phase 1, the physical properties and usability aspects of seven topical antiparasitic formulations were assessed. Within Phase 2, an ease-of-use study was conducted to evaluate the cat owners’ application experience with deidentified products representing three topical antiparasitics. Phase 3 included the identification and validation of product attributes most valued by pet owners through interviews with cat owners and veterinary experts. The product attributes identified informed the subsequent quantitative discrete choice experiment (DCE), which involved 1,040 cat owners from different countries and aimed to analyze their preferences based on choices among product profiles mirroring four topical antiparasitics: selamectin-sarolaner, moxidectin-fluralaner, moxidectin-imidacloprid, and eprinomectin-esafoxolaner-praziquantel. Phase 1 showed that the selamectin-sarolaner formulation exhibits minimal odor, less stickiness, and less drying time. The ease-of-use study (Phase 2) showed that the blinded product representing the selamectin-sarolaner formulation was characterized by seamless application, rapid dispensing, and a sense of control during application. The quantitative DCE study (Phase 3) indicated a preference for the product profile mirroring the selamectin-sarolaner formulation among a global sample of cat owners. Demographic characteristics such as gender, age, and insurance status influenced their preferences. Key predictors for preferring the selamectin-sarolaner formulation over at least one comparator treatment included the ability to confirm successful administration, age restrictions, ease of application, and the time before the cat could sit on furniture following administration. These findings suggest that cat owners prioritize ease of use, safety, and overall user experience, providing valuable guidance for veterinary practitioners to make informed treatment recommendations.

8 August 2024 in Animals
Verified
Journal Article
Open access
PDF file
AWAndrea Wright
Andrea Wright
EGEdwina Gildea
Edwina Gildea
LLLouise Longstaff
Louise Longstaff
DRDanielle Riley
Danielle Riley
NNNirav Nagda
Nirav Nagda
RWRobin Wyn
Robin Wyn
This research aimed to explore UK cat owners’ preferences for treatments for feline osteoarthritis (OA) by exploring preferences around quality of life (QoL) improvements, safety considerations, and costs associated with hypothetical innovative pain therapies. Aspects identified in an existing conceptual framework were extracted for inclusion in exploratory interviews with cat owners (n = 3) to identify key domains that contribute to the QoL of cats. QoL descriptions for cats with OA and hypothetical product attributes were developed and validated through interviews with veterinarians (n = 3). An online survey was subsequently shared with 255 pet owners in the UK. Pet owners were presented with QoL descriptions and hypothetical product attributes to gather their preferences for QoL improvements and their willingness to pay (WTP) for (unbranded) pain therapies at various price points. Pet owners were motivated to improve their cats’ QoL, which translated into WTP for therapies; specifically, pet owners valued QoL improvements in mobility, pain expression, and well-being. When presented with a product profile of the hypothetical novel monoclonal antibody (mAb) and cost, 50% of cat owners were willing to pay more for a mAb that is expected to have improved efficacy and safety when compared to a hypothetical standard of care (SoC). Significantly more pet owners preferred the mAb than the SoC when price was not presented (p < 0.01), with product efficacy and safety driving pet owners’ decision-making. The majority of pet owners did not agree that taking their cats to the veterinarian once a month for their treatment would be burdensome. Cat owners in the UK are motivated to improve their cats’ QoL, which translates into WTP for the efficacious treatment of pain associated with osteoarthritis. Veterinarians should offer cat owners the pain treatment they feel is best suited for improving the cat’s QoL and to ensure subsequent owner-pet bond is preserved.